Design, synthesis and evaluation of peroxisome proliferator-activated receptor α/γ dual agonists for the treatment of type 2 diabetes

被引：0

作者：

Das, Saibal Kumar ^{[1
]}

Abbineni, Chandrasekhar ^{[1
]}

Rao, Krovvidi Venkata Lakshmi Narasimha ^{[1
]}

Iqbal, Javed ^{[1
]}

Babu, Ravi Krishna ^{[1
]}

Chakrabarti, Ranjan ^{[1
]}

机构：

[1] Dr Reddys Labs Ltd, Metab Disorders Grp, Discovery Res, Hyderabad 500049, Andhra Pradesh, India

来源：

LETTERS IN DRUG DESIGN & DISCOVERY | 2007年 / 4卷 / 01期

关键词：

PPAR; diabetes; synthesis; ethyl 3-(4-aminophenyl)-2-ethoxypropionate; dyslipidemia and plasma glucose;

D O I：

暂无

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The design, synthesis and evaluation of several dual PPAR alpha/gamma agonists with three different heterocycles, viz. pyrazolo[4,3-d]pyrimidin-7-one, quinazolin-4-one and benzo[e][1,3]oxazine-4-one for the treatment of type 2 diabetes and associated dyslipidemia are described. Among them, compound 5cb was found to possess a potent dual PPAR alpha/gamma agonist property. It significantly reversed diabetic hyperglycemia while improving overall lipid homeostasis in preclinical animal models.

引用

页码：27 / 32

页数：6

共 50 条

[21] Design and Synthesis of Highly Active Peroxisome Proliferator-Activated Receptor (PPAR) / Inverse Agonists with Prolonged Cellular Activity
Toth, Philipp M.
Lieber, Sonja
Scheer, Frithjof M.
Schumann, Tim
Schober, Yvonne
Nockher, Wolfgang A.
Adhikary, Till
Mueller-Bruesselbach, Sabine
Mueller, Rolf
Diederich, Wibke E.
CHEMMEDCHEM, 2016, 11 (05) : 488 - 496
[22] Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus
Bajaj, M.
Suraamornkul, S.
Hardies, L. J.
Glass, L.
Musi, N.
DeFronzo, R. A.
DIABETOLOGIA, 2007, 50 (08) : 1723 - 1731
[23] Peroxisome proliferator-activated receptor (PPAR) modulators: Diabetes and beyond
Jones, AB
MEDICINAL RESEARCH REVIEWS, 2001, 21 (06) : 540 - 552
[24] Enantioselective Synthesis of PPAR (Peroxisome Proliferator-Activated Receptors) Agonists and Antagonists
Goya, Pilar
Perez-Fernandez, Ruth
Gonzalez-Muniz, Rosario
Elguero, Jose
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2014, 14 (10) : 1283 - 1293
[25] Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer’s disease
Rupinder K. Sodhi
Nirmal Singh
Amteshwar S. Jaggi
Naunyn-Schmiedeberg's Archives of Pharmacology, 2011, 384 : 115 - 124
[26] Review:: Peroxisome proliferator-activated receptor-γ and its role in the development and treatment of diabetes
Leff, T
Mathews, ST
Camp, HS
EXPERIMENTAL DIABESITY RESEARCH, 2004, 5 (02) : 99 - 109
[27] The use of hepatotoxic signals to predict the safety of peroxisome proliferator-activated receptor agonists
Hastings, Kenneth L.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2006, 2 (04) : 489 - 492
[28] Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer's disease
Sodhi, Rupinder K.
Singh, Nirmal
Jaggi, Amteshwar S.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2011, 384 (02) : 115 - 124
[29] Design and Synthesis of Dual Modulators of Soluble Epoxide Hydrolase and Peroxisome Proliferator-Activated Receptors
Buscato, Estella
Bloecher, Rene
Lamers, Christina
Klingler, Franca-Maria
Hahn, Steffen
Steinhilber, Dieter
Schubert-Zsilavecz, Manfred
Proschak, Ewgenij
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (23) : 10771 - 10775
[30] Peroxisome proliferator-activated receptor agonists as potential therapeutic agents in multiple sclerosis
Niino, Masaaki
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2007, 7 (11) : 1129 - 1135

← 1 2 3 4 5 →